The editors have included new authors and topics, and several chapters from second edition have been dropped. The overall organisation of the textbook has been changed in the light of changes of emphasis over the past 10 years. References have been restricted to create an overall succinct and comprehensive volume.
A chapter on novel therapies in clinical trials or pre-clinical trials will be added at the time of going to press. The editors have consolidated the gene therapy section from three to two chapters, and retitled the Section, The Future of Haemophilia Therapy. The chapter on Old Age in Haemophilia has been extended to include more about survivorship with HCV/HIV and perioperative management (+/- anticoagulation in association with post-stent/cardiothoracic surgery following MI).
Two areas that particularly needed reorganisation and rewriting were Inhibitors and Treatment to incorporate new products and future directions. Major new initiatives such as EUHASS have been incorporated. Furthermore, Ethical aspects of hemophilia care now merits a chapter on its own.
About the Author: Christine A. Lee, MA, MD, DSc, FRCP, FRCPath, Emeritus Professor of Haemophilia, University of London; Honorary Consultant Haematologist, Oxford Haemophilia & Thrombosis Centre, Oxford, UK.
Erik E. Berntorp, MD, PhD, Professor of Hemophilia, Lund University; Director, Department of Coagulation Disorders, Malmo University Hospital, Malmo, Sweden.
W. Keith Hoots, MD, Professor of Pediatrics, University of Texas M.D. Anderson Cancer Center; Professor of Pediatrics and Internal Medicine, University of Texas Medical School at Houston; Medical Director, Gulf States Hemophilia and Thrombophilia Center, Houston, Texas, USA.
